Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...

Anti-C1q antibodies are highly prevalent among patients with IgG4-RD, particularly those with renal and skin manifestations.

Although immune checkpoint inhibitors have shown noticeable clinical benefits, tumor evasion of single-agent immunotherapy occurs in some patients due to the compensatory role of alternative immune ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data ...

Kodiak Sciences uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies ...

The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, ...

The following is a summary of “Dual seropositive nonerosive lupus arthritis: rhupus or not?” published in the February 2025 ...